<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?OLF?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Acta Neurol Belg</journal-id><journal-id journal-id-type="iso-abbrev">Acta Neurol Belg</journal-id><journal-title-group><journal-title>Acta Neurologica Belgica</journal-title></journal-title-group><issn pub-type="ppub">0300-9009</issn><issn pub-type="epub">2240-2993</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7303437</article-id><article-id pub-id-type="publisher-id">1412</article-id><article-id pub-id-type="doi">10.1007/s13760-020-01412-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Neurological manifestations of COVID-19, SARS and MERS</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Verstrepen</surname><given-names>Kato</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Baisier</surname><given-names>Laure</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7582-5988</contrib-id><name><surname>De Cauwer</surname><given-names>Harald</given-names></name><address><email>harald.decauwer@ziekenhuisgeel.be</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Department of Neurology, Dimpna Regional Hospital, JB Stessenstraat 2, 2440 Geel, Belgium </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.5284.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 0790 3681</institution-id><institution>Faculty of Medicine and Health Sciences, University of Antwerp, </institution></institution-wrap>Wilrijk, Belgium </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>7</month><year>2020</year></pub-date><fpage>1</fpage><lpage>10</lpage><history><date date-type="received"><day>5</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>12</day><month>6</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; Belgian Neurological Society 2020</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Since December 2019, the world is affected by an outbreak of a new disease named COVID-19, which is an acronym of &#x02018;coronavirus disease 2019&#x02019;. Coronaviruses (CoV) were assumed to be associated with mild upper respiratory tract infections, such as common cold. This perception changed in time due to occurrence of the Severe Acute Respiratory Syndrome (SARS) caused by SARS-CoV in 2002 and the Middle East Respiratory Syndrome (MERS) caused by MERS-CoV in 2012, both inducing an epidemic severe viral pneumonia with potentially respiratory failure and numerous extra-pulmonary manifestations. The novel coronavirus, SARS-CoV-2, is likewise a causative pathogen for severe viral pneumonia with the risk of progression to respiratory failure and systemic manifestations. In this review, we will give a summary of the neurological manifestations due to SARS and MERS, as those might predict the neurological outcome in the novel COVID-19. Additionally, we provide an overview of the current knowledge concerning neurological manifestations associated with COVID-19, to the extent that literature is already available as the pandemic is still ongoing.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Neurology</kwd><kwd>COVID-19</kwd><kwd>SARS</kwd><kwd>MERS</kwd><kwd>Stroke</kwd><kwd>Neuropathy</kwd></kwd-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Viruses of the Coronaviridae family are positive-sensed, single-stranded RNA viruses. They are broadly distributed in different animal species including avian host, cats, dogs, bats, camels, cattle and mice. Among these viruses, some are pathogenic to human [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par3">In humans, CoV infections were primarily associated with upper respiratory tract and gastrointestinal tract infections. However, the last 2 decades the world was affected by several viral epidemics, such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) in 2002&#x02212;2003 and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in 2012, both resulting in high mortality rate, respectively, 10% and 35%.</p><p id="Par4">Since December 2019, the world is affected by an outbreak of a new disease named COVID-19, which is an acronym of &#x02018;coronavirus disease 2019&#x02019;. It is caused by a novel coronavirus (CoV), named SARS-CoV-2, due to similarities with the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par5">All three infections show a broad spectrum of clinical manifestation, varying from asymptomatic or mild disease to severe illness with risk of progress to respiratory failure due to viral pulmonary infection [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par6">It is known that human coronaviruses can reach the central nervous system (CNS) and that they could be associated with neurological symptoms [<xref ref-type="bibr" rid="CR6">6</xref>]. Several cases of neurological involvement during SARS and MERS and the potential mechanisms have already been described in literature [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par7">Conversely, despite the current global outbreak with many more patients affected, little is known about neurological manifestations in COVID-19 after 6&#x000a0;months. In this review, we will give an overview of these neurological manifestations reported due to SARS and MERS as this might be of great importance in dealing with the novel COVID-19. Additionally, we present a summary of the current knowledge&#x02014;still evolving in literature&#x02014;on neurological manifestations associated with SARS-CoV-2-infection.</p></sec><sec id="Sec2"><title>Method</title><sec id="Sec3"><title>Study selection</title><p id="Par8">The authors searched PubMed/MEDLINE databases in March 2020. Articles related to the topic were identified by following terms: &#x0201c;Severe Acute Respiratory Syndrome&#x0201d;, &#x0201c;Middle East Respiratory Syndrome&#x0201d;, Coronavirus disease 2019&#x0201d;, &#x0201c;Neurology&#x0201d;, &#x0201c;MERS&#x0201d;, &#x0201c;SARS&#x0201d;, &#x0201c;COVID-19&#x0201d;, &#x0201c;Stroke&#x0201d;, &#x0201c;Epilepsy&#x0201d;, &#x0201c;Guillain-Barr&#x000e9; Syndrome&#x0201d;, &#x0201c;Encephalitis&#x0201d;, &#x0201c;Myelitis&#x0201d;, &#x0201c;Meningitis&#x0201d;, &#x0201c;Neurological Sequels&#x0201d;, &#x0201c;Polyneuropathy&#x0201d; and &#x0201c;Carotid Dissection&#x0201d;.</p><p id="Par9">We used a date restriction ranging from the 1<sup>st</sup> of January 2002 until present. There were limited linguistic restrictions (articles in English, Dutch, French and German were eligible for inclusion).</p><p id="Par10">&#x0201c;Middle East Respiratory Syndrome&#x0201d; and &#x0201c;Neurology&#x0201d; identified 53 articles, of which 20 articles were retained based on review of title and abstract to select material for potential review. &#x0201c;Severe Acute Respiratory Syndrome&#x0201d; and &#x0201c;Neurology&#x0201d; revealed 102 articles, &#x0201c;Coronavirus disease 2019 and Neurology&#x0201d; revealed 1 article, &#x0201c;MERS&#x0201d; and &#x0201c;Neurology&#x0201d; 109 articles, &#x0201c;SARS&#x0201d; and &#x0201c;Neurology&#x0201d; 25 articles, &#x0201c;COVID- 19&#x0201d; and &#x0201c;Neurology&#x0201d; 5 articles, (&#x0201c;SARS&#x0201d; OR &#x0201c;MERS&#x0201d; OR &#x0201c;COVID-19&#x0201d;) and &#x0201c;Stroke&#x0201d; 17 articles, (&#x0201c;SARS&#x0201d; OR &#x0201c;MERS&#x0201d; OR &#x0201c;COVID-19&#x0201d;) and &#x0201c;Epilepsy&#x0201d; 15 articles, (&#x0201c;SARS&#x0201d; OR &#x0201c;MERS&#x0201d; OR &#x0201c;COVID-19&#x0201d;) and Guillain-Barr&#x000e9; syndrome&#x0201d; 3 articles, (&#x0201c;SARS&#x0201d; OR &#x0201c;MERS&#x0201d; OR &#x0201c;COVID-19&#x0201d;) and &#x0201c;Myelitis&#x0201d; 23 articles, (&#x0201c;SARS&#x0201d; OR &#x0201c;MERS&#x0201d; OR &#x0201c;COVID-19&#x0201d;) and &#x0201c;Carotid dissection&#x0201d; 1 articles, but after reviewing the titles and abstracts, no additional articles were retained. (&#x0201c;SARS&#x0201d; OR &#x0201c;MERS&#x0201d; OR &#x0201c;COVID-19&#x0201d;) and &#x0201c;Encephalitis&#x0201d; revealed 252 articles, of which 6 articles were selected for the review based on title and abstract. (&#x0201c;SARS&#x0201d; OR &#x0201c;MERS&#x0201d; OR &#x0201c;COVID-19&#x0201d;) and &#x0201c;Meningitis revealed 45 articles, of which 1 article was a potential result for the review. However, this article was only accessible in Danish and was not retained for this review. (&#x0201c;SARS&#x0201d; OR &#x0201c;MERS&#x0201d; OR &#x0201c;COVID-19&#x0201d;) and &#x0201c;Neurological sequels&#x0201d; revealed 47 articles, of which 3 were selected for the review. (&#x0201c;SARS&#x0201d; OR &#x0201c;MERS&#x0201d; OR &#x0201c;COVID-19&#x0201d;) and &#x0201c;Polyneuropathy&#x0201d; delivered 7 results, of which 1 was retained.</p><p id="Par11">The manuscripts that were considered as suitable for the review were evaluated via full text review. Interesting articles for our review noticed in the references of these articles, were used for additional information.</p></sec></sec><sec id="Sec4"><title>Results</title><sec id="Sec04"><title>Are coronaviruses related with neuro-inflammatory disease?</title><p id="Par12">Human coronaviruses (HCoV) are known to have neurotropic and neuro-invasive capabilities. Desforges et al. hypothesize human coronaviruses are neurovirulent, as they could contribute in short- and long-term neurological disorders such as encephalomyelitis and multiple sclerosis [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. The presence of HCoV RNA in the human CNS confirms these properties [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par13">Viruses, in general, may enter the brain and spinal cord via hematogenous or retrograde neuronal distribution. It is already known that HCoV can also spread from the respiratory tract to the central nervous system (CNS) through transneuronal and hematogenous routes [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par14">HCoV may persist in human brains, so it is assumed that long-term sequelae can develop related to emergence or aggravation of chronic neurological diseases, as it is already described for the human coronaviruses HCOV-229E and HCOV-OC43. The latter have been detected in various neurological diseases, including multiple sclerosis [<xref ref-type="bibr" rid="CR9">9</xref>]. Several recent articles report associated cases of encephalitis, acute flaccid paralysis and other neurological symptoms, such as Guillain-Barr&#x000e9; syndrome or ADEM, as possible complications of a HCoV infection [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par15">In this article, we will focus on the neurological manifestations described in SARS, MERS, and COVID-19.</p></sec><sec id="Sec5"><title>Initial clinical signs of SARS, MERS, and COVID-19 include non-specific neurological symptoms</title><p id="Par16">SARS may present with non-specific symptoms such as persistent fever, non-productive cough, myalgia, dyspnoea and headache. In roughly 20% of the patients, the initial presentation got complicated with acute respiratory distress syndrome [<xref ref-type="bibr" rid="CR6">6</xref>]. Aside from the respiratory tract, SARS-CoV infection may also target intestinal mucosal cells, renal tubular epithelial cells and neurons as well as cells from the lymphoid and reticuloendothelial system. As a consequence, extrapulmonary features including watery diarrhoea and vomiting may also be part of the clinical presentation. Furthermore, dizziness, nausea, decrease in general well-being and confusion have also been reported [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par17">The clinical presentation of MERS may also be non-specific. Runny nose, sore throat, low-grade fever and myalgia can present before the viremia becomes detectable [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. In case of severe disease, progression to acute respiratory distress may occur. Extrapulmonary manifestations including gastrointestinal symptoms and acute kidney failure have been reported in case of severe illness, as well as neurological manifestations [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par18">Common clinical features of COVID-19 include fever, cough, sore throat, headache, fatigue, myalgia, anosmia and dyspnoea. The infection may evolve into pneumonia, respiratory failure, multiple organ failure and death due to extreme rise in inflammatory cytokines [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p></sec><sec id="Sec6"><title>Neurological manifestations during evolving SARS</title><p id="Par19">Current data, mainly from Chinese brain autopsy studies, confirm CNS invasion by SARS-CoV [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par20">Cases described in the articles mentioned below concerning neurological manifestations reported during SARS-CoV-infection are rendered in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> [<xref ref-type="bibr" rid="CR3">3</xref>].<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Reported neurological manifestations associated with SARS-CoV-infection</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">References</th><th align="left">Patient</th><th align="left">Presenting neurological symptoms and signs</th><th align="left">Comorbidities</th><th align="left">Neurologic manifestation reported</th></tr></thead><tbody><tr><td align="left">Hung et al. [<xref ref-type="bibr" rid="CR15">15</xref>]</td><td align="left"><p>Patient 1</p><p>Female, 59 years</p></td><td align="left">Day 5 of admission: vomiting, episodes of four-limb twitching, confusion and disorientation</td><td align="left">IgA nephropathy</td><td align="left">Status epilepticus</td></tr><tr><td align="left">Wang et al. [<xref ref-type="bibr" rid="CR24">24</xref>]</td><td align="left"><p>Patient 1</p><p>Female, 38 years</p></td><td align="left">/</td><td align="left">/</td><td align="left">Rhabdomyolysis</td></tr><tr><td align="left"/><td align="left"><p>Patient 2,</p><p>Male, 52 years</p></td><td align="left">Myalgia, headache</td><td align="left">/</td><td align="left">Rhabdomyolysis</td></tr><tr><td align="left"/><td align="left">Patient 3, Female, 42 years</td><td align="left">/</td><td align="left">/</td><td align="left">Rhabdomyolysis</td></tr><tr><td align="left">Lau et al. [<xref ref-type="bibr" rid="CR9">9</xref>]</td><td align="left">Patient 1, Female, 32 years</td><td align="left">Day 22 of illness: generalized tonic-clinic convulsion, loss of consciousness, up-rolling eyeballs lasting for 1&#x000a0;min</td><td align="left">Week 26 of pregnancy</td><td align="left">Epilepsy</td></tr><tr><td align="left">Tsai et al. [<xref ref-type="bibr" rid="CR17">17</xref>]</td><td align="left">Patient 1, Female, 52 years</td><td align="left">Day 21 after onset SARS: weakness of 4 limbs, numbness of legs, mild hyporeflexia and hypesthesia in both legs</td><td align="left">/</td><td align="left">Polyradiculoneuropathy</td></tr><tr><td align="left"/><td align="left">Patient 2, Female, 48 years</td><td align="left">Day 24 after onset SARS: distal-predominant weakness of 4 limbs, numbness of bilateral fingers, mild hyporeflexia and hypesthesia to temperature and vibration in legs</td><td align="left">/</td><td align="left">Axonopathic sensorimotor polyneuropathy</td></tr><tr><td align="left"/><td align="left">Patient 3, Female, 42 years</td><td align="left">Day 25 after onset SARS: distal-predominant weakness of 4 limbs, numbness of left foot, proximal hyporeflexia, hypesthesia to temperature, pinprick and vibration in legs (left more distinct than right)</td><td align="left">/</td><td align="left">Myopathy with superimposed asymmetric sensorimotor polyneuropathy of axonopathic type</td></tr><tr><td align="left"/><td align="left">Patient 4, Male, 31 years</td><td align="left">Day 22 after onset SARS: weakness of proximal lower limbs, weakness of bilateral hip flexor muscles</td><td align="left">/</td><td align="left">Myopathy</td></tr><tr><td align="left">Umapathi et al. [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td align="left">Patient 1 Female, 68 years</td><td align="left">Persistent unconsciousness after withdrawal of paralytic and sedative drugs. Acute hypotension.</td><td align="left">/</td><td align="left">Infarctions in left posterior and middle cerebral artery</td></tr><tr><td align="left"/><td align="left">Patient 2, Female, 64 years</td><td align="left"><p>Episode of transient hypotension.</p><p>9&#x000a0;days after admission to intensive care unit: dilated, unreactive right pupil, absence oculocephalic reflex, flaccid limbs.</p></td><td align="left">/</td><td align="left">Massive right infarction in middle cerebral artery with early hydrocephalus</td></tr><tr><td align="left"/><td align="left"><p>Patient 3</p><p>Female, 54 years</p></td><td align="left"><p>15&#x000a0;days after admission: central diabetes insipidus, acute hypotension</p><p>Few days later: dilated pupils showing poor reaction, absence of oculocephalic reflex, flaccid limbs</p></td><td align="left">Dyslipidaemia, treated hyperthyroidism</td><td align="left">Large infarction in left posterior cerebral artery and bilateral middle cerebral artery</td></tr><tr><td align="left"/><td align="left"><p>Patient 4</p><p>Male, 63 years</p></td><td align="left">14&#x000a0;days after admission: partial left hemispheric syndrome</td><td align="left">Diabetes, hypertension, ischemic heart disease</td><td align="left">Left temporo-parietal infarction</td></tr><tr><td align="left"/><td align="left">Patient 5 Male 39 years</td><td align="left">No neurological deficits noted before death</td><td align="left">/</td><td align="left">Autopsy: infarction in inferior lateral part of right occipital lobe</td></tr><tr><td align="left">Leung et al.[<xref ref-type="bibr" rid="CR19">19</xref>]</td><td align="left"><p>Patient 1</p><p>Male, 44 years</p></td><td align="left">Myalgia, acute flaccid paresis</td><td align="left">Chronic hepatitis B</td><td align="left">Steroid myopathy, critical illness myopathy</td></tr><tr><td align="left"/><td align="left"><p>Patient 2</p><p>Male, 64 years</p></td><td align="left">Progressive myalgia and symmetric muscle weakness (truncal, proximal limbs and neck flexors)</td><td align="left">Diabetes mellitus, alcoholic cirrhosis</td><td align="left">Steroid myopathy, critical illness myopathy</td></tr><tr><td align="left"/><td align="left"><p>Patient 3</p><p>Male, 79 years</p></td><td align="left">Progressive myalgia and symmetric muscle weakness (truncal, proximal limbs and neck flexors)</td><td align="left">Ischemic heart disease</td><td align="left">Steroid myopathy, critical illness myopathy</td></tr><tr><td align="left"/><td align="left"><p>Patient 4</p><p>Male, 76 years</p></td><td align="left">Progressive myalgia and symmetric muscle weakness (truncal, proximal limbs and neck flexors)</td><td align="left">Myelodysplastic syndrome</td><td align="left">Steroid myopathy, critical illness myopathy</td></tr><tr><td align="left"/><td align="left"><p>Patient 5</p><p>Male, 69 years</p></td><td align="left">Progressive myalgia and symmetric muscle weakness (truncal, proximal limbs and neck flexors)</td><td align="left">Chronic rheumatic heart disease</td><td align="left">SARS-associated myopathy due to immune response</td></tr><tr><td align="left"/><td align="left"><p>Patient 6</p><p>Female, 81 years</p></td><td align="left">Progressive myalgia and symmetric muscle weakness (truncal, proximal limbs and neck flexors)</td><td align="left">Parkinson disease and carcinoma of lung</td><td align="left">SARS-associated myopathy due to immune response</td></tr><tr><td align="left"/><td align="left"><p>Patient 7</p><p>Male, 49 years</p></td><td align="left">Progressive myalgia and symmetric muscle weakness (truncal, proximal limbs and neck flexors)</td><td align="left">Hepatitis B and cirrhosis</td><td align="left">SARS-associated myopathy due to immune response</td></tr><tr><td align="left"/><td align="left"><p>Patient 8</p><p>Male, 81 years</p></td><td align="left">Progressive myalgia and symmetric muscle weakness (truncal, proximal limbs and neck flexors)</td><td align="left">Chronic gastric ulcer and severe aortic regurgitation</td><td align="left">SARS-associated myopathy due to immune response</td></tr><tr><td align="left">Xu et al. [<xref ref-type="bibr" rid="CR14">14</xref>]</td><td align="left"><p>Patient 1</p><p>Male, 39 years</p></td><td align="left"><p>Day 26 after onset of illness: obscured monocular vision</p><p>Day 28: progressive CNS symptoms including dysphoria, vomiting, deliria (due to progression of left lower lobe consolidation)</p><p>Day 33: coma after admission of intravenous sedative.</p></td><td align="left">/</td><td align="left">Ischemia and necrosis of brain seen on CT</td></tr><tr><td align="left">Hwang [<xref ref-type="bibr" rid="CR25">25</xref>]</td><td align="left"><p>Patient 1</p><p>Female, 27 years</p></td><td align="left">Complete anosmia in both sides</td><td align="left">/</td><td align="left">Acute olfactory neuropathy</td></tr></tbody></table></table-wrap></p><sec id="Sec7"><title>Epilepsy</title><p id="Par21">Hung et al. described the first evidence of entry of SARS-CoV in cerebrospinal fluid (CSF) causing seizures. They reported a case of a 59-year-old woman, who experienced a status epilepticus associated with SARS. Both serum and CSF tested positive for SARS-RNA by RT-PCR [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par22">Lau et al. reported a case of a 32-year-old female who developed a generalized tonic&#x02013;clonic insult on day 22 of illness with SARS-CoV being detected in the CSF by RT-PCR [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par23">Another impact of the SARS-epidemic was the adverse effect on seizure control due to withdrawal of anti-epileptic drug treatment as many patients avoided hospital visits [<xref ref-type="bibr" rid="CR16">16</xref>].</p></sec><sec id="Sec8"><title>Neuromuscular disorders</title><p id="Par24">Neuromuscular disorders in SARS are predominantly late-onset sequelae and include critical-illness polyneuropathy and myopathy [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par25">Muscle weakness and elevated serum creatine kinase levels occur in more than 30% of patients with SARS [<xref ref-type="bibr" rid="CR18">18</xref>]. In patients with fatal SARS, Leung et al. examined post-mortem histological muscle samples and described a myopathy, either resulting from critical illness myopathy or from the immune response against SARS-CoV [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par26">Critical illness myopathy and critical illness polyneuropathy can both occur in a context entitled the systemic inflammatory response syndrome (SIRS). SIRS is a term comprising sepsis and multiple organ failure, which can both be aspects of SARS-CoV-infections and be related to excessive production of tumour necrosis factor alfa and nitric oxide in the macrophages [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>]</p><p id="Par27">Rhabdomyolysis has previously been associated with many infectious diseases, but it is rarely seen in SARS-CoV-infection [<xref ref-type="bibr" rid="CR23">23</xref>]. In a case series, rhabdomyolysis correlated with renal failure and was considered to be a severe manifestation of SARS. Therefore, creatine kinase levels of SARS-patients should be monitored thoroughly [<xref ref-type="bibr" rid="CR24">24</xref>].</p></sec><sec id="Sec9"><title>Olfactory neuropathy</title><p id="Par28">In contrast to frequent occurrence of anosmia in early stages of COVID-19 (see below), it is anecdotal in SARS and only described in late stage of the disease. Nevertheless, olfactory function test should be part of routine work-up for patients with SARS [<xref ref-type="bibr" rid="CR25">25</xref>].</p></sec><sec id="Sec10"><title>Stroke</title><p id="Par29">Five cases of large artery ischaemic stroke were described in SARS. It is suggested that a pro-coagulant state could be present in patients with SARS [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. This could contribute to large cerebral arterial thromboembolism, together with factors as systemic hypotension and cardiac dysfunction. However, stroke is not uncommon in critically ill patients with co-morbidity. Furthermore, it is believed that the use of intravenous immunoglobulins, used to treat SARS, could play a role in SARS-related stroke. Hyperviscosity induced by intravenous immunoglobulins in patients already prone to hypercoagulable state due to viral infection and the inflammatory response, could play a key role in stroke [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>].</p></sec><sec id="Sec11"><title>Chronic post-SARS syndrome and autonomic dysfunction</title><p id="Par30">Chronic post-SARS syndrome was described by Moldofsky et al. The syndrome is characterized by persistent fatigue, diffuse myalgia, weakness, depression, nonrestorative sleep with associated REM-related apneas/hypopneas, an elevated sleep EEG cyclical alternating pattern and alpha EEG sleep anomaly [<xref ref-type="bibr" rid="CR28">28</xref>].</p><p id="Par31">Other authors suggest that prolonged fatigue and malaise may be linked to peripheral and autonomic nervous system dysfunction. Chronic fatigue may be present months after recovery from acute illness. One study shows autonomic dysfunction to be present in 50% of recovered SARS-patients. Subclinical orthostatic hemodynamic disturbances would lead to fatigue and dizziness [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>].</p></sec></sec><sec id="Sec12"><title>Neurological manifestations associated with MERS-CoV infection</title><p id="Par32">Cases described in the articles mentioned below concerning neurological manifestations reported during MERS-CoV-infection are rendered in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Reported neurological manifestations associated with MERS-CoV-infection</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Reference</th><th align="left">Patient</th><th align="left">Presenting neurological symptoms</th><th align="left">Comorbidities</th><th align="left">Neurological manifestations reported</th></tr></thead><tbody><tr><td align="left">Arabi et al.[<xref ref-type="bibr" rid="CR35">35</xref>]</td><td align="left"><p>Patient 1</p><p>Male, 74 years</p></td><td align="left"><p>Ataxia, vomiting, confusion.</p><p>Clinical neurologic examination revealed dysmetria and decreased motor strenght on left side</p></td><td align="left">Hypertension, dyslipidemia and diabetes</td><td align="left">Findings consistent with acute disseminated encephalomyelitis (ADEM) or less probably encephalitis</td></tr><tr><td align="left"/><td align="left"><p>Patient 2</p><p>Male, 57 years</p></td><td align="left">Day 5 of hospitalization: unresponsiveness, hypotensive with left-sided facial paralysis</td><td align="left">Hypertension, diabetes and peripheral vascular disease</td><td align="left">Acute bilaterally non-occlusive stroke probably due to MERS-CoV-Vasculopathy</td></tr><tr><td align="left"/><td align="left"><p>Patient 3</p><p>Male, 45 years</p></td><td align="left">Day 24 of hospitalization: low Glasgow coma scale and fever</td><td align="left">Hypertension, diabetes, chronic kidney disease, ischemic heart disease</td><td align="left">Findings consistent with encephalitis</td></tr><tr><td align="left">Algahtani et al. [<xref ref-type="bibr" rid="CR33">33</xref>]</td><td align="left"><p>Patient 1</p><p>Female, 34 years</p></td><td align="left">Day 14 of hospitalization: severe headache, nausea and vomiting, decreased level of consciousness and Glasgow Coma Scale of 3/15</td><td align="left">Diabetes mellitus</td><td align="left">Right frontal lobe intracerebral hemorrhage</td></tr><tr><td align="left"/><td align="left"><p>Patient 2</p><p>Male, 28 years</p></td><td align="left">Weakness in both legs and inability to walk with numbness and tingling in stocking distribution</td><td align="left">/</td><td align="left">Critical illness polyneuropathy</td></tr><tr><td align="left">Al-Hameed et al. [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left"><p>Patient</p><p>Female, 42 years</p></td><td align="left">Day 13 of hospitalization: polyuric with urine osmolarity of 95&#x000a0;meq/L and serum osmolarity of 341&#x000a0;meq/L, unresponsiveness, GCS of 3/15, pupil diameter of 3&#x000a0;mm with sluggish reaction</td><td align="left">Diabetes mellitus type 2, obesities</td><td align="left">Spontaneous massive intracranial hemorrhage</td></tr></tbody></table></table-wrap></p><sec id="Sec13"><title>CNS involvement</title><p id="Par33">Although it is exceptional, the CNS could be involved by MERS-CoV infection, mostly due to auto-immune reaction through autoreactive T-cells which recognize viral and myelin antigens as similar molecules, rather than to viral infection itself [<xref ref-type="bibr" rid="CR31">31</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref>].</p><p id="Par34">A retrospective study in Saudi Arabia stated that about 25% of MERS patients developed confusion and 8.6% experienced a seizure [<xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par35">Another case series of three patients with altered level of consciousness varying from confusion to coma, ataxia and focal motor deficit, describes diffuse CNS disease with MRI showing new onset, widespread, bilateral hyperintense lesions on T2-weighted imaging within white matter and subcortical areas of different lobes, basal ganglia, corpus callosum, pons, cerebellum and upper cervical cord with only non-specific increased protein level in CSF.</p><p id="Par36">Final working diagnoses in the three patients were respectively acute disseminated encephalomyelitis, acute bilateral non-occlusive stroke due to MERS-CoV vasculopathy and encephalitis [<xref ref-type="bibr" rid="CR35">35</xref>].</p><p id="Par37">The negative CSF for MERS-CoV RT-PCR might be due to the timing of the test, the lack of meningeal involvement as shown on MRI, or the virus being located intra-neuronally as reported with SARS-CoV [<xref ref-type="bibr" rid="CR36">36</xref>].</p><p id="Par38">Intracerebral haemorrhage as result of thrombocytopenia, disseminated intravascular coagulation and platelet dysfunction, is very rare [<xref ref-type="bibr" rid="CR32">32</xref>].</p><p id="Par39">In 2007, Al-Hameed et al. described the case of a female health care worker who developed a sudden-onset diabetes insipidus and spontaneous massive intracranial haemorrhage with intra-ventricular extension and tonsillar herniation. Her platelet count and coagulation profile did not show any abnormalities. As mentioned in the table, the woman was obese. The severity of MERS in obese patients can be explained as dipeptidyl peptidase 4 (DPP4), a transmembrane protein involved in cell entry of viruses such as MERS-CoV, is overexpressed in obese patients [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>].</p></sec><sec id="Sec14"><title>Neuromuscular disorders</title><p id="Par40">Only one case of a 28-year-old male, an orthopaedic resident, was reported. After a long stay in intensive care, he suffered from weakness in both legs and inability to walk, along with numbness and tingling in stocking distribution. He was diagnosed with critical illness polyneuropathy [<xref ref-type="bibr" rid="CR32">32</xref>].</p></sec><sec id="Sec15"><title>Iatrogenic neurological pathology during treatment of MERS</title><p id="Par41">Kim et al. published a case report of four patients who developed neurological manifestations during treatment of MERS. A triple antiviral treatment, consisting of subcutaneous pegylated interferon alpha-2a, high-dose oral ribavirin and oral lopinavir/ritonavir, was administered to all patients in the concerned hospital. Characteristics, presentation and diagnosis of the reported patients experiencing neurological symptoms during their treatment of MERS-CoV-infection are summarized in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> [<xref ref-type="bibr" rid="CR39">39</xref>].<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Clinical presentation and diagnosis of patients with MERS who experienced neurological complications due to treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Reference</th><th align="left">Patient</th><th align="left">Presenting neurological symptoms</th><th align="left">Comorbidities</th><th align="left">Neurologic manifestation reported</th></tr></thead><tbody><tr><td align="left">Kim et al. [<xref ref-type="bibr" rid="CR39">39</xref>]</td><td align="left"><p>Patient 1</p><p>Male, 55 years</p></td><td align="left">Day 24 after initial onset of respiratory symptoms: hypersomnolence, weakness and ataxia and hyporeflexia in all limbs, bilateral ptosis and external ophthalmoplegia,</td><td align="left">Diabetes mellitus, hypertension, chronic kidney disease, hypothyroidism, atrial fibrillation</td><td align="left">Bickerstaff&#x02019;s encephalitis overlapping with Guillain-Barr&#x000e9; syndrome</td></tr><tr><td align="left"/><td align="left"><p>Patient 2</p><p>Female, 43 years</p></td><td align="left">Day 16 after MERS onset: tingling and stinging pain sensation in both and below knees, bilateral proximal dominant weakness in legs, hyporeflexia in both legs</td><td align="left">/</td><td align="left">ICU-acquired weakness or Guillain-Barr&#x000e9; syndrome</td></tr><tr><td align="left"/><td align="left"><p>Patient 3</p><p>Male, 46 years</p></td><td align="left">Day 20 after MERS onset: tingling sensation in distal parts of hands and feet, hypesthesia in distal parts of all limbs, bilateral hyporeflexia in legs</td><td align="left">Hypertension, pulmonary tuberculosis</td><td align="left">Infectious or toxic polyneuropathy</td></tr><tr><td align="left"/><td align="left"><p>Patient 4</p><p>Female, 38 years</p></td><td align="left">Day 21 after MERS onset: tingling in both hands</td><td align="left"/><td align="left">Acute sensory neuropathy caused by toxin or infection</td></tr></tbody></table></table-wrap></p><p id="Par42">Interferon alpha-2a is a possible causative drug for peripheral neuropathy, sensory neuropathy, vasculitic neuropathy, Bell&#x02019;s palsy, Guillain Barr&#x000e9; Syndrome, chronic inflammatory demyelinating polyneuropathy and autonomic polyneuropathy [<xref ref-type="bibr" rid="CR40">40</xref>&#x02013;<xref ref-type="bibr" rid="CR42">42</xref>]. Lopinavir/ritonavir is another possible causative drug for peripheral neuropathy [<xref ref-type="bibr" rid="CR43">43</xref>]. Ribavirine is not associated with peripheral neuropathy [<xref ref-type="bibr" rid="CR42">42</xref>].</p></sec></sec><sec id="Sec16"><title>Neurological manifestations associated with SARS-CoV-2 infection</title><p id="Par43">Similar to SARS-CoV, SARS-CoV-2 profits from the angiotensin converting enzyme 2 receptor (ACE2-R) to infiltrate in the intracellular space. It has been described that the brain expresses ACE2-R, which have been detected in glial cells and neurons as well as endothelial cells and smooth muscle cells. Therefore, these cells and neurons are potential targets of COVID-19 [<xref ref-type="bibr" rid="CR44">44</xref>] COVID-19 may reach the central nervous system via the systemic circulation or via the cribriform plate of the ethmoid bone during an early or later phase of the infection as has been reported in SARS-CoV [<xref ref-type="bibr" rid="CR45">45</xref>] Once the neuronal tissues are reached, the interaction between SARS-CoV-2 and ACE2-R can initiate a cycle of viral growth with co-occurrence of neuronal damage without substantial inflammation as has been seen with cases of SARS-CoV [<xref ref-type="bibr" rid="CR45">45</xref>].</p><p id="Par44">What does this mean in the clinical setting?</p><sec id="Sec17"><title>Neurological symptoms in early disease stages</title><p id="Par45">These are similar to SARS and MERS and merely non-specific including dizziness, nausea, vomiting, and headache [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>].</p><p id="Par46">Hypogeusia and hyposmia are frequently reported and have become a cardinal factor in the early diagnosis of COVID-19 [<xref ref-type="bibr" rid="CR46">46</xref>].</p><p id="Par47">Most probably, this is caused by direct invasion of the olfactory bulb when SARS-CoV-2 makes its entry into the skull via the cribriform plate [<xref ref-type="bibr" rid="CR44">44</xref>].</p><p id="Par48">A recent German report states that it seems to be well distinguishable from a post-infectious olfactory disorder following rhinitis or another upper respiratory tract infection: most of the patients describe a rather sudden, almost complete loss of odour (i.e. mostly anosmia, less often hyposmia). COVID-19 patients are less likely to have other nasal symptoms such as nasal breathing obstruction, clinically manifest rhinitis or excessive nasal secretions [<xref ref-type="bibr" rid="CR48">48</xref>].</p></sec><sec id="Sec18"><title>Acute Inflammatory Demyelinating Polyneuropathy can precede respiratory disease</title><p id="Par49">By the end of April 2020, after 4&#x000a0;months of evolving pandemic, Guillain Barr&#x000e9; syndrome (GBS) was reported in less than ten COVID-19-patients, but more cases are in press.</p><p id="Par50">Most of the cases occurred in the early stage of COVID-19 in patients presenting with only minor respiratory symptoms at onset of GBS. Although it is notable that the disease severity for both the GBS and pneumonia can deteriorate simultaneously [<xref ref-type="bibr" rid="CR49">49</xref>&#x02013;<xref ref-type="bibr" rid="CR51">51</xref>].</p><p id="Par51">One report described GBS in a patient without any respiratory symptoms, but with loss of smell and taste preceding GBS [<xref ref-type="bibr" rid="CR52">52</xref>].</p></sec><sec id="Sec19"><title>Cerebrovascular disease during COVID-19</title><p id="Par52">A variety of cerebrovascular disorders has been recently reported, probably due to endothelial dysfunction, or hypercoagulability in COVID-19 patients.</p><p id="Par53">These disorders include ischemic stroke, intracerebral hemorrhage, and cerebral venous sinus thrombosis [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR54">54</xref>&#x02013;<xref ref-type="bibr" rid="CR56">56</xref>]. Cerebrovascular disease was associated with poor outcome (more respiratory distress, more multi-organ dysfunction, and higher mortality) of COVID-19 patients [<xref ref-type="bibr" rid="CR56">56</xref>].</p></sec></sec></sec><sec id="Sec20"><title>Conclusion</title><p id="Par54">The three major outbreaks of corona viruses (SARS-CoV, MERS-CoV, and SARS-CoV-2) show similarities in neurological manifestations, but also some differences.</p><p id="Par55">Due to the hospital emergency plan and the splitting of hospitals in hot zones versus cold zones to prevent hospital clusters of corona-infection, neurological work up is limited to bedside clinical evaluation, spinal fluid analysis and CT scan. MRI imaging is mostly located in the cold zone, thus limited available for infected patients. A surveillance of neurological manifestations (Guillain-Barr&#x000e9; syndrome, meningoencephalitis, stroke&#x02026;) in these patients is warranted as is surveillance for thromboembolic sequelae (pulmonary embolism, stroke). Many patients present with fever, respiratory symptoms, but also headache, anosmia, dizziness. However, spinal tap is not routinely performed and literature on spinal fluid analysis is very sparse. An explanation for the lack of CSF-data would be that there is currently no validated test to detect SARS-CoV-2 in CSF. A multidisciplinary approach and more neurology consultations in the emergency department and COVID-19-wards could prevent under-diagnosing of neurological complications and thus insufficient treatment. Rapid diagnosis and proper treatment of Guillain-Barr&#x000e9; syndrome, critical illness polyneuropathy, stroke, and other neurological disorders could have a positive impact on outcome. As the COVID-19 pandemic is evolving, our knowledge on the neurological manifestations of COVID-19 is also evolving. Although the current pandemic is of a much higher scale than SARS and MERS, and far more neurological cases could be expected, the thusfar available literature about neurological manifestation of COVID-19 is rather limited. This review will hopefully contribute to increased alertness for both neurologists and non-neurologists involved in the care of COVID-19 patients.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="ethics"><title>Compliance with ethical standards</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par57">All the authors report no disclosure nor conflict of interest relevant to the manuscript. All authors report no financial disclosure.</p></notes><notes id="FPar2"><title>Ethical approval</title><p id="Par58">This manuscript does not contain any studies with human participants or animals performed by any of the authors.
</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R (2020) Features, evaluation and treatment coronavirus (COVID-19). StatPearls. Treasure Island (FL): StatPearls Publishing. StatPearls Publishing LLC</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunha</surname><given-names>CB</given-names></name><name><surname>Opal</surname><given-names>SM</given-names></name></person-group><article-title>Middle East respiratory syndrome (MERS): a new zoonotic viral pneumonia</article-title><source>Virulence</source><year>2014</year><volume>5</volume><issue>6</issue><fpage>650</fpage><lpage>654</lpage><?supplied-pmid 25089913?><pub-id pub-id-type="pmid">25089913</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Niu</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title><source>The Lancet</source><year>2020</year><volume>395</volume><issue>10224</issue><fpage>565</fpage><lpage>574</lpage></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradley</surname><given-names>BT</given-names></name><name><surname>Bryan</surname><given-names>A</given-names></name></person-group><article-title>Emerging respiratory infections: the infectious disease pathology of SARS, MERS, pandemic influenza, and Legionella</article-title><source>Semin Diagn Pathol</source><year>2019</year><volume>36</volume><issue>3</issue><fpage>152</fpage><lpage>159</lpage><?supplied-pmid 31054790?><pub-id pub-id-type="pmid">31054790</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>DSC</given-names></name><name><surname>Zumla</surname><given-names>A</given-names></name></person-group><article-title>Severe acute respiratory syndrome: historical, epidemiologic, and clinical features</article-title><source>Infect Dis Clin North Am</source><year>2019</year><volume>33</volume><issue>4</issue><fpage>869</fpage><lpage>889</lpage><?supplied-pmid 31668196?><pub-id pub-id-type="pmid">31668196</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desforges</surname><given-names>M</given-names></name><name><surname>Le Coupanec</surname><given-names>A</given-names></name><name><surname>Dubeau</surname><given-names>P</given-names></name><name><surname>Bourgouin</surname><given-names>A</given-names></name><name><surname>Lajoie</surname><given-names>L</given-names></name><name><surname>Dub&#x000e9;</surname><given-names>M</given-names></name><etal/></person-group><article-title>Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system?</article-title><source>Viruses.</source><year>2019</year><volume>12</volume><issue>1</issue><fpage>14</fpage></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>KK</given-names></name><name><surname>Yu</surname><given-names>WC</given-names></name><name><surname>Chu</surname><given-names>CM</given-names></name><name><surname>Lau</surname><given-names>ST</given-names></name><name><surname>Sheng</surname><given-names>B</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name></person-group><article-title>Possible central nervous system infection by SARS coronavirus</article-title><source>Emerg Infect Dis</source><year>2004</year><volume>10</volume><issue>2</issue><fpage>342</fpage><lpage>344</lpage><?supplied-pmid 15030709?><pub-id pub-id-type="pmid">15030709</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>EA</given-names></name><name><surname>Collins</surname><given-names>A</given-names></name><name><surname>Cohen</surname><given-names>ME</given-names></name><name><surname>Duffner</surname><given-names>PK</given-names></name><name><surname>Faden</surname><given-names>H</given-names></name></person-group><article-title>Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis</article-title><source>Pediatrics</source><year>2004</year><volume>113</volume><issue>1 Pt 1</issue><fpage>e73</fpage><lpage>e76</lpage><?supplied-pmid 14702500?><pub-id pub-id-type="pmid">14702500</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arbour</surname><given-names>N</given-names></name><name><surname>Day</surname><given-names>R</given-names></name><name><surname>Newcombe</surname><given-names>J</given-names></name><name><surname>Talbot</surname><given-names>PJ</given-names></name></person-group><article-title>Neuroinvasion by human respiratory coronaviruses</article-title><source>J Virol</source><year>2000</year><volume>74</volume><issue>19</issue><fpage>8913</fpage><lpage>8921</lpage><?supplied-pmid 102086?><pub-id pub-id-type="pmid">10982334</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desforges</surname><given-names>M</given-names></name><name><surname>Le Coupanec</surname><given-names>A</given-names></name><name><surname>Stodola</surname><given-names>JK</given-names></name><name><surname>Meessen-Pinard</surname><given-names>M</given-names></name><name><surname>Talbot</surname><given-names>PJ</given-names></name></person-group><article-title>Human coronaviruses: viral and cellular factors involved in neuroinvasiveness and neuropathogenesis</article-title><source>Virus Res</source><year>2014</year><volume>194</volume><fpage>145</fpage><lpage>158</lpage><?supplied-pmid 25281913?><pub-id pub-id-type="pmid">25281913</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arabi</surname><given-names>YM</given-names></name><name><surname>Balkhy</surname><given-names>HH</given-names></name><name><surname>Hayden</surname><given-names>FG</given-names></name><name><surname>Bouchama</surname><given-names>A</given-names></name><name><surname>Luke</surname><given-names>T</given-names></name><name><surname>Baillie</surname><given-names>JK</given-names></name><etal/></person-group><article-title>Middle East Respiratory Syndrome</article-title><source>N Engl J Med</source><year>2017</year><volume>376</volume><issue>6</issue><fpage>584</fpage><lpage>594</lpage><?supplied-pmid 5362064?><pub-id pub-id-type="pmid">28177862</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian journal of pediatrics. 2020</mixed-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Multiple organ infection and the pathogenesis of SARS</article-title><source>J Exp Med</source><year>2005</year><volume>202</volume><issue>3</issue><fpage>415</fpage><lpage>424</lpage><?supplied-pmid 2213088?><pub-id pub-id-type="pmid">16043521</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Zhong</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis</article-title><source>Clin infect Dis</source><year>2005</year><volume>41</volume><issue>8</issue><fpage>1089</fpage><lpage>1096</lpage><?supplied-pmid 16163626?><pub-id pub-id-type="pmid">16163626</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>EC</given-names></name><name><surname>Chim</surname><given-names>SS</given-names></name><name><surname>Chan</surname><given-names>PK</given-names></name><name><surname>Tong</surname><given-names>YK</given-names></name><name><surname>Ng</surname><given-names>EK</given-names></name><name><surname>Chiu</surname><given-names>RW</given-names></name><etal/></person-group><article-title>Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome</article-title><source>Clin Chem</source><year>2003</year><volume>49</volume><issue>12</issue><fpage>2108</fpage><lpage>2109</lpage><?supplied-pmid 14633896?><pub-id pub-id-type="pmid">14633896</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>SL</given-names></name><name><surname>Hsu</surname><given-names>MT</given-names></name><name><surname>Chen</surname><given-names>SS</given-names></name></person-group><article-title>The impact of SARS on epilepsy: the experience of drug withdrawal in epileptic patients</article-title><source>Seizure.</source><year>2005</year><volume>14</volume><issue>8</issue><fpage>557</fpage><lpage>561</lpage><?supplied-pmid 16188463?><pub-id pub-id-type="pmid">16188463</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>LK</given-names></name><name><surname>Hsieh</surname><given-names>ST</given-names></name><name><surname>Chao</surname><given-names>CC</given-names></name><name><surname>Chen</surname><given-names>YC</given-names></name><name><surname>Lin</surname><given-names>YH</given-names></name><name><surname>Chang</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Neuromuscular disorders in severe acute respiratory syndrome</article-title><source>Arch Neurol</source><year>2004</year><volume>61</volume><issue>11</issue><fpage>1669</fpage><lpage>1673</lpage><?supplied-pmid 15534177?><pub-id pub-id-type="pmid">15534177</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>N</given-names></name><name><surname>Hui</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>P</given-names></name><name><surname>Cameron</surname><given-names>P</given-names></name><name><surname>Joynt</surname><given-names>GM</given-names></name><etal/></person-group><article-title>A major outbreak of severe acute respiratory syndrome in Hong Kong</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><issue>20</issue><fpage>1986</fpage><lpage>1994</lpage><?supplied-pmid 12682352?><pub-id pub-id-type="pmid">12682352</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>TW</given-names></name><name><surname>Wong</surname><given-names>KS</given-names></name><name><surname>Hui</surname><given-names>AC</given-names></name><name><surname>To</surname><given-names>KF</given-names></name><name><surname>Lai</surname><given-names>ST</given-names></name><name><surname>Ng</surname><given-names>WF</given-names></name><etal/></person-group><article-title>Myopathic changes associated with severe acute respiratory syndrome: a postmortem case series</article-title><source>Arch Neurol</source><year>2005</year><volume>62</volume><issue>7</issue><fpage>1113</fpage><lpage>1117</lpage><?supplied-pmid 16009768?><pub-id pub-id-type="pmid">16009768</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zochodne</surname><given-names>DW</given-names></name></person-group><article-title>SARS, SIRS, and neurological disease</article-title><source>Arch Neurol</source><year>2004</year><volume>61</volume><issue>11</issue><fpage>1647</fpage><lpage>1648</lpage><?supplied-pmid 15534173?><pub-id pub-id-type="pmid">15534173</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Bock</surname><given-names>F</given-names></name><name><surname>Derijard</surname><given-names>B</given-names></name><name><surname>Dornand</surname><given-names>J</given-names></name><name><surname>Bockaert</surname><given-names>J</given-names></name><name><surname>Rondouin</surname><given-names>G</given-names></name></person-group><article-title>The neuronal death induced by endotoxic shock but not that induced by excitatory amino acids requires TNF-alpha</article-title><source>Eur J Neurosci</source><year>1998</year><volume>10</volume><issue>10</issue><fpage>3107</fpage><lpage>3114</lpage><?supplied-pmid 9786205?><pub-id pub-id-type="pmid">9786205</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>H&#x000f6;ke</surname><given-names>A</given-names></name><name><surname>Zochodne</surname><given-names>DW</given-names></name></person-group><article-title>Local expression of inducible nitric oxide synthase in an animal model of neuropathic pain</article-title><source>Neurosci Lett</source><year>1999</year><volume>260</volume><issue>3</issue><fpage>207</fpage><lpage>209</lpage><?supplied-pmid 10076904?><pub-id pub-id-type="pmid">10076904</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>U</given-names></name><name><surname>Scheld</surname><given-names>WM</given-names></name></person-group><article-title>Infectious Etiologies of Rhabdomyolysis: three Case Reports and Review</article-title><source>Clin Infect Dis</source><year>1996</year><volume>22</volume><issue>4</issue><fpage>642</fpage><lpage>649</lpage><?supplied-pmid 8729203?><pub-id pub-id-type="pmid">8729203</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J-L</given-names></name><name><surname>Wang</surname><given-names>J-T</given-names></name><name><surname>Yu</surname><given-names>C-J</given-names></name><name><surname>Chen</surname><given-names>Y-C</given-names></name><name><surname>Hsueh</surname><given-names>P-R</given-names></name><name><surname>Hsiao</surname><given-names>C-H</given-names></name><etal/></person-group><article-title>Rhabdomyolysis associated with probable SARS</article-title><source>Am J Med</source><year>2003</year><volume>115</volume><issue>5</issue><fpage>421</fpage><lpage>422</lpage><?supplied-pmid 14553890?><pub-id pub-id-type="pmid">14553890</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>CS</given-names></name></person-group><article-title>Olfactory neuropathy in severe acute respiratory syndrome: report of A case</article-title><source>Acta Neurol Taiwan</source><year>2006</year><volume>15</volume><issue>1</issue><fpage>26</fpage><lpage>28</lpage><?supplied-pmid 16599281?><pub-id pub-id-type="pmid">16599281</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalakas</surname><given-names>MC</given-names></name><name><surname>Clark</surname><given-names>WM</given-names></name></person-group><article-title>Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record</article-title><source>Neurology</source><year>2003</year><volume>60</volume><issue>11</issue><fpage>1736</fpage><lpage>1737</lpage><?supplied-pmid 12796522?><pub-id pub-id-type="pmid">12796522</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umapathi</surname><given-names>T</given-names></name><name><surname>Kor</surname><given-names>AC</given-names></name><name><surname>Venketasubramanian</surname><given-names>N</given-names></name><name><surname>Lim</surname><given-names>CC</given-names></name><name><surname>Pang</surname><given-names>BC</given-names></name><name><surname>Yeo</surname><given-names>TT</given-names></name><etal/></person-group><article-title>Large artery ischaemic stroke in severe acute respiratory syndrome (SARS)</article-title><source>J Neurol</source><year>2004</year><volume>251</volume><issue>10</issue><fpage>1227</fpage><lpage>1231</lpage><?supplied-pmid 15503102?><pub-id pub-id-type="pmid">15503102</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moldofsky</surname><given-names>H</given-names></name><name><surname>Patcai</surname><given-names>J</given-names></name></person-group><article-title>Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study</article-title><source>BMC Neurol</source><year>2011</year><volume>11</volume><fpage>37</fpage><?supplied-pmid 21435231?><pub-id pub-id-type="pmid">21435231</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>YL</given-names></name><name><surname>Leong</surname><given-names>HN</given-names></name><name><surname>Hsu</surname><given-names>LY</given-names></name><name><surname>Tan</surname><given-names>TT</given-names></name><name><surname>Kurup</surname><given-names>A</given-names></name><name><surname>Fook-Chong</surname><given-names>S</given-names></name><etal/></person-group><article-title>Autonomic dysfunction in recovered severe acute respiratory syndrome patients</article-title><source>Canad J Neurol Sci</source><year>2005</year><volume>32</volume><issue>2</issue><fpage>264</fpage><?supplied-pmid 16018168?><pub-id pub-id-type="pmid">16018168</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>KW</given-names></name><name><surname>Chau</surname><given-names>TN</given-names></name><name><surname>Tsang</surname><given-names>O</given-names></name><name><surname>Tso</surname><given-names>E</given-names></name><name><surname>Chiu</surname><given-names>MC</given-names></name><name><surname>Tong</surname><given-names>WL</given-names></name><etal/></person-group><article-title>Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong</article-title><source>Ann Intern Med</source><year>2003</year><volume>139</volume><issue>9</issue><fpage>715</fpage><lpage>723</lpage><?supplied-pmid 14597455?><pub-id pub-id-type="pmid">14597455</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Hameed</surname><given-names>FM</given-names></name></person-group><article-title>Spontaneous intracranial hemorrhage in a patient with Middle East respiratory syndrome corona virus</article-title><source>Saudi Med J</source><year>2017</year><volume>38</volume><issue>2</issue><fpage>196</fpage><lpage>200</lpage><?supplied-pmid 28133694?><pub-id pub-id-type="pmid">28133694</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Algahtani</surname><given-names>H</given-names></name><name><surname>Subahi</surname><given-names>A</given-names></name><name><surname>Shirah</surname><given-names>B</given-names></name></person-group><article-title>Neurological complications of middle east respiratory syndrome coronavirus: a report of two cases and review of the literature</article-title><source>Case Rep Neurol Med</source><year>2016</year><volume>2016</volume><fpage>3502683</fpage><?supplied-pmid 27239356?><pub-id pub-id-type="pmid">27239356</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joob</surname><given-names>B</given-names></name><name><surname>Wiwanitkit</surname><given-names>V</given-names></name></person-group><article-title>Neurologic syndrome due to MERS: is there a possibility that the virus can cross the blood-brain barrier to cause a neurological problem?</article-title><source>Ann Trop Med Publ Health</source><year>2015</year><volume>8</volume><issue>5</issue><fpage>231</fpage></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saad</surname><given-names>M</given-names></name><name><surname>Omrani</surname><given-names>AS</given-names></name><name><surname>Baig</surname><given-names>K</given-names></name><name><surname>Bahloul</surname><given-names>A</given-names></name><name><surname>Elzein</surname><given-names>F</given-names></name><name><surname>Matin</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Clinical aspects and outcomes of 70 patients with middle east respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia</article-title><source>Int J Infect Dis</source><year>2014</year><volume>29</volume><fpage>301</fpage><lpage>306</lpage><?supplied-pmid 25303830?><pub-id pub-id-type="pmid">25303830</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arabi</surname><given-names>YM</given-names></name><name><surname>Harthi</surname><given-names>A</given-names></name><name><surname>Hussein</surname><given-names>J</given-names></name><name><surname>Bouchama</surname><given-names>A</given-names></name><name><surname>Johani</surname><given-names>S</given-names></name><name><surname>Hajeer</surname><given-names>AH</given-names></name><etal/></person-group><article-title>Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV)</article-title><source>Infection</source><year>2015</year><volume>43</volume><issue>4</issue><fpage>495</fpage><lpage>501</lpage><?supplied-pmid 25600929?><pub-id pub-id-type="pmid">25600929</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Korteweg</surname><given-names>C</given-names></name></person-group><article-title>Pathology and pathogenesis of severe acute respiratory syndrome</article-title><source>Am J Pathol</source><year>2007</year><volume>170</volume><issue>4</issue><fpage>1136</fpage><lpage>1147</lpage><?supplied-pmid 17392154?><pub-id pub-id-type="pmid">17392154</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>VS</given-names></name><name><surname>Mou</surname><given-names>H</given-names></name><name><surname>Smits</surname><given-names>SL</given-names></name><name><surname>Dekkers</surname><given-names>DH</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>MA</given-names></name><name><surname>Dijkman</surname><given-names>R</given-names></name><etal/></person-group><article-title>Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC</article-title><source>Nature</source><year>2013</year><volume>495</volume><issue>7440</issue><fpage>251</fpage><lpage>254</lpage><?supplied-pmid 23486063?><pub-id pub-id-type="pmid">23486063</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamers</surname><given-names>D</given-names></name><name><surname>Famulla</surname><given-names>S</given-names></name><name><surname>Wronkowitz</surname><given-names>N</given-names></name><name><surname>Hartwig</surname><given-names>S</given-names></name><name><surname>Lehr</surname><given-names>S</given-names></name><name><surname>Ouwens</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome</article-title><source>Diabetes</source><year>2011</year><volume>60</volume><issue>7</issue><fpage>1917</fpage><lpage>1925</lpage><?supplied-pmid 21593202?><pub-id pub-id-type="pmid">21593202</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JE</given-names></name><name><surname>Heo</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>HO</given-names></name><name><surname>Song</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>SS</given-names></name><name><surname>Park</surname><given-names>TH</given-names></name><etal/></person-group><article-title>Neurological Complications during Treatment of Middle East Respiratory Syndrome</article-title><source>Journal of clinical neurology (Seoul, Korea).</source><year>2017</year><volume>13</volume><issue>3</issue><fpage>227</fpage><lpage>233</lpage><?supplied-pmid 28748673?><pub-id pub-id-type="pmid">28748673</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briani</surname><given-names>C</given-names></name><name><surname>Chemello</surname><given-names>L</given-names></name><name><surname>Zara</surname><given-names>G</given-names></name><name><surname>Ermani</surname><given-names>M</given-names></name><name><surname>Bernardinello</surname><given-names>E</given-names></name><name><surname>Ruggero</surname><given-names>S</given-names></name><etal/></person-group><article-title>Peripheral neurotoxicity of pegylated interferon alpha. A prospective study in patients with HCV</article-title><source>Neurology</source><year>2006</year><volume>67</volume><issue>5</issue><fpage>781</fpage><lpage>785</lpage><?supplied-pmid 16966537?><pub-id pub-id-type="pmid">16966537</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meriggioli</surname><given-names>MN</given-names></name><name><surname>Rowin</surname><given-names>J</given-names></name></person-group><article-title>Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha</article-title><source>Muscle Nerve</source><year>2000</year><volume>23</volume><issue>3</issue><fpage>433</fpage><lpage>435</lpage><?supplied-pmid 10679722?><pub-id pub-id-type="pmid">10679722</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khiani</surname><given-names>V</given-names></name><name><surname>Kelly</surname><given-names>T</given-names></name><name><surname>Shibli</surname><given-names>A</given-names></name><name><surname>Jensen</surname><given-names>D</given-names></name><name><surname>Mohanty</surname><given-names>SR</given-names></name></person-group><article-title>Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon alpha 2a therapy for chronic hepatitis C virus infection</article-title><source>World J Gastroenterol</source><year>2008</year><volume>14</volume><issue>2</issue><fpage>318</fpage><lpage>321</lpage><?supplied-pmid 18186575?><pub-id pub-id-type="pmid">18186575</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>RJ</given-names></name><name><surname>Marquie-Beck</surname><given-names>J</given-names></name><name><surname>Delaney</surname><given-names>P</given-names></name><name><surname>Alexander</surname><given-names>T</given-names></name><name><surname>Clifford</surname><given-names>DB</given-names></name><name><surname>McArthur</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy</article-title><source>Ann Neurol</source><year>2008</year><volume>64</volume><issue>5</issue><fpage>566</fpage><lpage>572</lpage><?supplied-pmid 19067367?><pub-id pub-id-type="pmid">19067367</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baig</surname><given-names>AM</given-names></name><name><surname>Khaleeq</surname><given-names>A</given-names></name><name><surname>Ali</surname><given-names>U</given-names></name><name><surname>Syeda</surname><given-names>H</given-names></name></person-group><article-title>Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms</article-title><source>ACS Chem Neurosci</source><year>2020</year><volume>11</volume><issue>7</issue><fpage>995</fpage><lpage>998</lpage><?supplied-pmid 32167747?><pub-id pub-id-type="pmid">32167747</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netland</surname><given-names>J</given-names></name><name><surname>Meyerholz</surname><given-names>DK</given-names></name><name><surname>Moore</surname><given-names>S</given-names></name><name><surname>Cassell</surname><given-names>M</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2</article-title><source>J Virol</source><year>2008</year><volume>82</volume><issue>15</issue><fpage>7264</fpage><lpage>7275</lpage><?supplied-pmid 18495771?><pub-id pub-id-type="pmid">18495771</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">Mao L, Wang M, Chen S, He Q, Chang J, Hong C, et al. Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study. medRxiv. 2020:2020.02.22.20026500</mixed-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>YC</given-names></name><name><surname>Bai</surname><given-names>WZ</given-names></name><name><surname>Hashikawa</surname><given-names>T</given-names></name></person-group><article-title>The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients</article-title><source>J Med Virol</source><year>2020</year><volume>92</volume><issue>6</issue><fpage>552</fpage><lpage>555</lpage><?supplied-pmid 32104915?><pub-id pub-id-type="pmid">32104915</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000fc;ers</surname><given-names>JC</given-names></name><name><surname>Klu&#x000df;mann</surname><given-names>JP</given-names></name><name><surname>Guntinas-Lichius</surname><given-names>O</given-names></name></person-group><article-title>The Covid-19 pandemic and otolaryngology: What it comes down to?</article-title><source>Laryngo- Rhino- Otologie.</source><year>2020</year><volume>99</volume><issue>5</issue><fpage>287</fpage><lpage>291</lpage><?supplied-pmid 32215896?><pub-id pub-id-type="pmid">32215896</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Shen</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name></person-group><article-title>Guillain-Barr&#x000e9; syndrome associated with SARS-CoV-2 infection: causality or coincidence?</article-title><source>Lancet Neurol</source><year>2020</year><volume>19</volume><issue>5</issue><fpage>383</fpage><lpage>384</lpage><?supplied-pmid 32246917?><pub-id pub-id-type="pmid">32246917</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Otmani</surname><given-names>H</given-names></name><name><surname>El Moutawakil</surname><given-names>B</given-names></name><name><surname>Rafai</surname><given-names>MA</given-names></name><name><surname>El Benna</surname><given-names>N</given-names></name><name><surname>El Kettani</surname><given-names>C</given-names></name><name><surname>Soussi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Covid-19 and Guillain-Barr&#x000e9; syndrome: more than a coincidence!</article-title><source>Revue neurologique.</source><year>2020</year><volume>176</volume><issue>6</issue><fpage>518</fpage><lpage>519</lpage><?supplied-pmid 32359804?><pub-id pub-id-type="pmid">32359804</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ottaviani</surname><given-names>D</given-names></name><name><surname>Boso</surname><given-names>F</given-names></name><name><surname>Tranquillini</surname><given-names>E</given-names></name><name><surname>Gapeni</surname><given-names>I</given-names></name><name><surname>Pedrotti</surname><given-names>G</given-names></name><name><surname>Cozzio</surname><given-names>S</given-names></name><etal/></person-group><article-title>Early Guillain-Barr&#x000e9; syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital</article-title><source>Neurol Sci</source><year>2020</year><volume>2020</volume><fpage>1</fpage><lpage>4</lpage></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheidl</surname><given-names>E</given-names></name><name><surname>Canseco</surname><given-names>DD</given-names></name><name><surname>Hadji-Naumov</surname><given-names>A</given-names></name><name><surname>Bereznai</surname><given-names>B</given-names></name></person-group><article-title>Guillain-Barre syndrome during SARS-CoV-2 pandemic: a case report and review of recent literature</article-title><source>Journal of the peripheral nervous system: JPNS.</source><year>2020</year><pub-id pub-id-type="doi">10.1111/jns.12382</pub-id><?supplied-pmid 32388880?><pub-id pub-id-type="pmid">32388880</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>MF</given-names></name><name><surname>Goldberg</surname><given-names>MF</given-names></name><name><surname>Cerejo</surname><given-names>R</given-names></name><name><surname>Tayal</surname><given-names>AH</given-names></name></person-group><article-title>Cerebrovascular Disease in COVID-19</article-title><source>AJNR American journal of neuroradiology.</source><year>2020</year><pub-id pub-id-type="doi">10.3174/ajnr.A6588</pub-id><?supplied-pmid 32646949?><pub-id pub-id-type="pmid">32646949</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hess</surname><given-names>DC</given-names></name><name><surname>Eldahshan</surname><given-names>W</given-names></name><name><surname>Rutkowski</surname><given-names>E</given-names></name></person-group><article-title>COVID-19-related stroke</article-title><source>Translational stroke research.</source><year>2020</year><volume>11</volume><issue>3</issue><fpage>322</fpage><lpage>325</lpage><?supplied-pmid 32378030?><pub-id pub-id-type="pmid">32378030</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>C</given-names></name><name><surname>Nichols</surname><given-names>T</given-names></name><name><surname>Pike</surname><given-names>M</given-names></name><name><surname>Subbe</surname><given-names>C</given-names></name><name><surname>Elghenzai</surname><given-names>S</given-names></name></person-group><article-title>Cerebral venous sinus thrombosis as a presentation of COVID-19</article-title><source>European J Case Rep int Med</source><year>2020</year><volume>7</volume><issue>5</issue><fpage>001691</fpage></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pranata</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>I</given-names></name><name><surname>Lim</surname><given-names>MA</given-names></name><name><surname>Wahjoepramono</surname><given-names>PEJ</given-names></name><name><surname>July</surname><given-names>J</given-names></name></person-group><article-title>Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19 - systematic review, meta-analysis, and meta-regression</article-title><source>J Stroke Cerebrovasc Dis</source><year>2020</year><volume>2020</volume><fpage>104949</fpage></element-citation></ref></ref-list></back></article>